Key Insights

Highlights

Success Rate

77% trial completion

Published Results

102 trials with published results (13%)

Research Maturity

320 completed trials (41% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.5%

98 terminated out of 783 trials

Success Rate

76.6%

-9.9% vs benchmark

Late-Stage Pipeline

0%

3 trials in Phase 3/4

Results Transparency

32%

102 of 320 completed with results

Key Signals

102 with results77% success98 terminated

Data Visualizations

Phase Distribution

779Total
Not Applicable (8)
Early P 1 (16)
P 1 (725)
P 2 (27)
P 3 (2)
P 4 (1)

Trial Status

Completed320
Recruiting181
Terminated98
Unknown81
Not Yet Recruiting47
Active Not Recruiting43

Trial Success Rate

76.6%

Benchmark: 86.5%

Based on 320 completed trials

Clinical Trials (783)

Showing 20 of 20 trials
NCT07266428Phase 1RecruitingPrimary

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

NCT07534813Not ApplicableNot Yet RecruitingPrimary

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

NCT06959706Phase 1RecruitingPrimary

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

NCT06799637Phase 1RecruitingPrimary

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

NCT06741644Phase 1RecruitingPrimary

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

NCT06596473Phase 1RecruitingPrimary

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT07509684Phase 1Not Yet RecruitingPrimary

A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

NCT05879627Phase 1TerminatedPrimary

To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors

NCT06178614Phase 1Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

NCT07524348Phase 1RecruitingPrimary

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

NCT06832982Phase 1RecruitingPrimary

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

NCT06555744Phase 1RecruitingPrimary

A Study of ZW191 in Participants With Solid Tumors

NCT07172919Phase 2RecruitingPrimary

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT04626635Phase 1RecruitingPrimary

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT07161414Phase 1RecruitingPrimary

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT06760819Phase 2RecruitingPrimary

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05083481Phase 1Active Not RecruitingPrimary

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

NCT04222413Phase 1RecruitingPrimary

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT07262619Phase 1RecruitingPrimary

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT02693535Phase 2Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Scroll to load more

Research Network

Activity Timeline